Based on the maximum concentration (Cmax) and the area under the curve (AUCall), we administered a dose of 5 μg and 10 μg of BC281 vs BC462 per injection every 3 days for a total of 6 doses in the immunocompetent MLL-AF9 leukemia model (Fig. 5H). The gene discussed is KMT2A; the disease is leukemia.